Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures
- 1Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany
- 2Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University Clinic, Heidelberg, Heidelberg, Germany
In the recent years, circulating microRNAs (miRNAs) have garnered a lot of attention and interest in the field of disease biomarkers. With characteristics such as high stability, low cost, possibility of repeated sampling and minimal invasiveness, circulating miRNAs are ideal for development into diagnostic tests. There have been many studies reported on the potential of circulating miRNAs as early detection, prognostic, and predictive biomarkers in cancer. Here, we have reviewed the application of plasma and serum miRNAs as biomarkers for cancer focusing on epithelial carcinomas [prostate, breast, lung, colorectal, and gastric cancer (GC)] and hematological malignancies (leukemia and lymphoma). We have also addressed the common challenges that need to be overcome to achieve a successful bench to bedside transition.
Keywords: circulating miRNA, cancer, biomarkers, prognostic marker, detection marker
Citation: Madhavan D, Cuk K, Burwinkel B and Yang R (2013) Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front. Genet. 4:116. doi: 10.3389/fgene.2013.00116
Received: 22 April 2013; Accepted: 01 June 2013;
Published online: 21 June 2013.
Edited by:Arun Bhardwaj, University of South Alabama Mitchell Cancer Institute, USA
Reviewed by:Sumit Arora, University of south Alabama, USA
Tarun K. Sharma, Translational Health Science and Technology Institute, India
Copyright © 2013 Madhavan, Cuk, Burwinkel and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: Dharanija Madhavan, Molecular Epidemiology, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany; Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University Clinic, Heidelberg, Vossstrasse 9, D-69115 Heidelberg, Germany e-mail: firstname.lastname@example.org
†These authors have contributed equally to this work.